$34.31
3.25% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US23282W6057
Symbol
CYTK

Cytokinetics, Incorporated Stock price

$34.31
-4.27 11.07% 1M
-7.87 18.66% 6M
-12.73 27.06% YTD
-21.87 38.93% 1Y
-15.99 31.79% 3Y
+12.39 56.52% 5Y
+27.53 406.05% 10Y
-22.27 39.36% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+1.08 3.25%

Key metrics

Basic
Market capitalization
$4.0b
Enterprise Value
$3.7b
Net debt
positive
Cash
$938.2m
Shares outstanding
119.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
206.9 | 169.4
EV/Sales
192.3 | 157.4
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-9.7%
Return on Equity
435.5%
ROCE
-51.2%
ROIC
-
Debt/Equity
-2.5
Financials (TTM | estimate)
Revenue
$19.2m | $23.5m
EBITDA
$-556.1m | $-667.1m
EBIT
$-565.6m | $-644.3m
Net Income
$-615.3m | $-668.6m
Free Cash Flow
$-407.6m
Growth (TTM | estimate)
Revenue
411.2% | 27.1%
EBITDA
-14.5% | -26.7%
EBIT
-13.6% | -20.1%
Net Income
-16.0% | -13.4%
Free Cash Flow
3.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-2,893.9% | -2,841.5%
EBIT
-2,943.3%
Net
-3,201.5% | -2,848.0%
Free Cash Flow
-2,120.8%
More
EPS
$-5.2
FCF per Share
$-3.4
Short interest
17.4%
Employees
498
Rev per Employee
$40.0k
Show more

Is Cytokinetics, Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Cytokinetics, Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Cytokinetics, Incorporated forecast:

22x Buy
81%
5x Hold
19%

Analyst Opinions

27 Analysts have issued a Cytokinetics, Incorporated forecast:

Buy
81%
Hold
19%

Financial data from Cytokinetics, Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
19 19
411% 411%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 227 227
34% 34%
1,182%
- Research and Development Expense 358 358
8% 8%
1,861%
-556 -556
15% 15%
-2,894%
- Depreciation and Amortization 9.50 9.50
23% 23%
49%
EBIT (Operating Income) EBIT -566 -566
14% 14%
-2,943%
Net Profit -615 -615
16% 16%
-3,201%

In millions USD.

Don't miss a Thing! We will send you all news about Cytokinetics, Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cytokinetics, Incorporated Stock News

Neutral
Seeking Alpha
4 days ago
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants & - Corporate Participant Andrew M. Callos - Executive VP & Chief Commercial Officer Diane Weiser - Senior Vice President of Corporate Affairs Fady Ibraham Malik - Executive Vice President of Research Development Robert I.
Neutral
The Motley Fool
5 days ago
CYTK Earnings Jump 3,065%
Neutral
GlobeNewsWire
5 days ago
Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China;  Late-Cycle Meeting with U.S. FDA Scheduled for September Ahead of December 26, 2025 PDUFA Date
More Cytokinetics, Incorporated News

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Head office United States
CEO Robert Blum
Employees 498
Founded 1997
Website cytokinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today